Christina M. Annunziata, MD, PhD, investigator, Women's Malignancies Branch, head, Translational Genomics Section, National Cancer Institute, discusses focusing efforts to prevent gynecologic cancers.

Researchers need to think about treating patients earlier and determining how to prevent cancer from forming in the first place, she explains. There needs to be more examinations in high-risk groups and identify patients who are at risk for these gynecologic cancers—then work to help prevent a cancer diagnosis from occurring.

Progress is being made for therapies in the upfront and recurrent settings, but there needs to be more of a push in the prevention setting, she concludes.

Videos

Christina M. Annunziata, MD, PhD, investigator, Women's Malignancies Branch, head, Translational Genomics Section, National Cancer Institute, discusses the importance on efforts being done to prevent gynecologic cancers.

Dr. Annunziata on Efforts to Prevent Gynecologic Cancers

Christina M. Annunziata, MD, PhD, head, Translational Genomics Section, National Cancer Institute, discusses the phase II/III study of olaparib (Lynparza) and cediranib for patients with platinum-resistant ovarian cancer.

In the phase II setting, an initial signal of activity and safety will be investigated for each of the 4 arms, explains Annunziata. Currently, there are no data regarding these drugs in the platinum-resistant setting.

This study will then move on to the phase III setting to compare the combination with the standard of care.

Christina M. Annunziata, MD, PhD

Articles

Dr. Annunziata on Efforts to Prevent Gynecologic Cancers

Dr. Annunziata on Olaparib and Cediranib Combination in Ovarian Cancer